Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with brain metastases and/or leptomeningeal carcinomatosis
2019-001739-29Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Mar 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, brain metastases and Carcinomatous Meningitis (CM), sponsored by MEDSIR. Primary endpoint: Primary endpoint (Cohort 1). Started Mar 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancerbrain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on 2019-001739-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001739-29.